Polymerase chain reaction-based assay for antibody-mediated neutralization of HIV-1 reveals a population of nonneutralized virus undetected by conventional p24 assay

Journal of Acquired Immune Deficiency Syndromes

Volumn 24, Issue 3, 2000, Pages 203-210

  Achkar, Jacqueline M ^a   Wang, Xiao Hong ^a   Nyambi, Phillipe ^a   Gorny, Miroslaw K ^a   Zolla Pazner, Susan ^a   Bandrés, Juan C ^a,b  

^a NEW YORK UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

HIV antibodies; HIV 1 Neutralization; Polymerase chain reaction

Indexed keywords

CD4 ANTIGEN DERIVATIVE; GAG PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 694 98 D; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; MOLECULAR CLONING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; STRAIN DIFFERENCE; VIRUS DETECTION; VIRUS NEUTRALIZATION;

EID: 0034232814     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200007010-00002     Document Type: Article

References (43)

1. Mechanisms contributing to the neutralization of HIV-1
2. Neutralization of animal viruses
3. A resting cell assay for improved detection of antibody-mediated neutralization of HIV type 1 primary isolates
4. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 isolates: Effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells
5. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates
6. Two antigenically distinct subtypes of HIV-1: Viral genotype predicts neutralization immunotype
7. Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies
8. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120
9. Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization
10. A rapid, automated microtiter assay for measuring neutralization of HIV-1
11. Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein
12. Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 by antisera raised against gp120 from the MN isolate of HIV-1
13. Synergistic inhibition of HIV-1 by CD4 binding domain reagents and V3-directed monoclonal antibodies
14. Neutralization of HIV-1
15. Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody
16. Neutralization of diverse human immunodeficiency virus type 1 variants by anti-V3 human monoclonal antibody
17. Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage
18. A bioassay for HIV-1 based on env-CD4 interaction
19. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene
20. Expression cloning of new receptors used by simian and human immunodeficiency viruses
21. HIV neutralization assay using polymerase chain reaction-derived molecular signals
22. Two PBMC-based neutralization assays depict low reactivity of both anti-V3 monoclonal antibodies and immune sera against HIV-1 primary isolates
23. Passive immunization with a human immunodeficiency virus type 1-neutralizing monoclonal antibody in Hu-PBL-SCID mice: Isolation of a neutralization escape variant
24. Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia
25. Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines
26. HIV-1 Nef protein downregulation of CD4 surface expression: Relevance of the lck binding domain of CD4
27. Biological and biochemical characterization of a cloned Leu-3-cell surviving infection with the acquired immune deficiency syndrome retrovirus
28. Phylogenetic and serological characterization of two Ugandan HIV-1 isolates
29. Endpoint method-measurement of the infectious titer of a viral sample
30. Detection and analysis of HIV
31. Complete nucleotide sequence of functional clones of the AIDS virus
32. Similarities and diversity among human monoclonal antibodies to the CD4-binding domain of HIV-1
33. Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp-120
34. Host cell-dependent alterations in envelope components of human immunodeficiency virus type 1 virions
35. Adenovirus DNA replication in vitro
36. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: An international collaboration
37. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody
38. Hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120
39. Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human rnonoclonal antibody against the gp120 CD4-binding site
40. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1
41. Linear versus conformational variation of V3 neutralization domains of HIV-1 during experimental and natural infection
42. Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees
43. Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitution that cause changes in antibody binding at multiple sites